-
公开(公告)号:US20180118708A1
公开(公告)日:2018-05-03
申请号:US15572231
申请日:2016-05-06
发明人: Toshitake KOBAYASHI , Morihisa SAITOH , Yasufumi WADA , Hiroshi NARA , Nobuyuki NEGORO , Masashi YAMASAKI , Takahiro TANAKA , Naomi KITAMOTO
CPC分类号: C07D317/72 , A61K31/357 , A61P1/16 , A61P9/10 , A61P25/02 , A61P29/00 , A61P37/00
摘要: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of autoimmune disease and/or inflammatory disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like.The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
-
公开(公告)号:US20190300536A1
公开(公告)日:2019-10-03
申请号:US16366710
申请日:2019-03-27
发明人: Yuya OGURO , Shigemitsu MATSUMOTO , Takeshi WAKABAYASHI , Norihito TOKUNAGA , Taku KAMEI , Mitsuhiro ITO , Satoshi MIKAMI , Masaki SETO , Shinji MORIMOTO , Shinji NAKAMURA , Sachie TAKASHIMA , Masataka MURAKAMI , Masaki DAINI , Makoto KAMATA , Minoru NAKAMURA , Yasufumi WADA , Hiroyuki KAKEI , Kazuaki TAKAMI , Taisuke TAWARAISHI , Jumpei AIDA , Kouichi IWANAGA , Satoshi YAMAMOTO
IPC分类号: C07D487/04 , C07D471/04 , A61K9/20 , A61K9/48
摘要: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
-
公开(公告)号:US20220274982A1
公开(公告)日:2022-09-01
申请号:US17630840
申请日:2020-07-28
发明人: Yuta TANAKA , Yuta TANAKA , Fumiaki KIKUCHI , Takeshi YAMAMOTO , Minoru NAKAMURA , Kazuaki TAKAMI , Masataka MURAKAMI , Masaki DAINI , Yasufumi WADA , Keiko KAKEGAWA , Takahito KASAHARA , Tomohiro OHASHI , Junsi WANG , Zenichi IKEDA , Florian PUENNER , Masaki SETO , Satoshi MIKAMI , Minoru SASAKI
IPC分类号: C07D471/04
摘要: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号:US20190233370A1
公开(公告)日:2019-08-01
申请号:US16331962
申请日:2017-09-07
发明人: Toshitake KOBAYASHI , Morihisa SAITOH , Yasufumi WADA , Nobuyuki NEGORO , Masashi YAMASAKI , Takahiro TANAKA , Naomi KITAMOTO
摘要: The present invention provides a compound having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI).The present invention relates to ethyl 6-((2-chloro-4-fluorobenzyl)sulfonyl)-3-hydroxycyclohex-1-ene-1-carboxylate or an optical isomer thereof.
-
公开(公告)号:US20160326102A1
公开(公告)日:2016-11-10
申请号:US15148210
申请日:2016-05-06
发明人: Toshitake Kobayashi , Morihisa SAITOH , Yasufumi WADA , Hiroshi NARA , Nobuyuki NEGORO , Taisuke KATOH , Masashi YAMASAKI , Takahiro TANAKA , Naomi KITAMOTO
IPC分类号: C07C317/12 , C07D309/28 , C07D317/72
CPC分类号: C07D317/72 , C07C317/12 , C07C317/44 , C07C317/46 , C07C2601/16 , C07C2602/08 , C07D309/28
摘要: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like.The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
摘要翻译: (其中,在说明书中更详细地说明每个符号)。
-
公开(公告)号:US20210332053A1
公开(公告)日:2021-10-28
申请号:US17201878
申请日:2021-03-15
发明人: Yuya OGURO , Shigemitsu MATSUMOTO , Takeshi WAKABAYASHI , Norihito TOKUNAGA , Taku KAMEI , Mitsuhiro ITO , Satoshi MIKAMI , Masaki SETO , Shinji MORIMOTO , Shinji NAKAMURA , Sachie TAKASHIMA , Masataka MURAKAMI , Masaki DAINI , Makoto KAMATA , Minoru NAKAMURA , Yasufumi WADA , Hiroyuki KAKEI , Kazuaki TAKAMI , Taisuke TAWARAISHI , Jumpei AIDA , Kouichi IWANAGA , Satoshi YAMAMOTO
IPC分类号: C07D487/04 , A61K9/20 , A61K9/48 , C07D471/04 , A61P25/00
摘要: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号:US20170066737A1
公开(公告)日:2017-03-09
申请号:US15356906
申请日:2016-11-21
发明人: Toshitake Kobayashi , Morihisa SAITOH , Yasufumi WADA , Hiroshi NARA , Nobuyuki NEGORO , Taisuke KATOH , Masashi YAMASAKI , Takahiro TANAKA , Naomi KITAMOTO
IPC分类号: C07D317/72 , C07C317/46 , C07D309/28 , C07C317/44
CPC分类号: C07D317/72 , C07C317/12 , C07C317/44 , C07C317/46 , C07C2601/16 , C07C2602/08 , C07D309/28
摘要: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.
摘要翻译: 其中,在说明书中更详细地说明每个符号。
-
公开(公告)号:US20160326133A1
公开(公告)日:2016-11-10
申请号:US15175292
申请日:2016-06-07
发明人: Toshitake Kobayashi , Morihisa SAITOH , Yasufumi WADA , Hiroshi NARA , Nobuyuki NEGORO , Taisuke KATOH , Masashi YAMASAKI , Takahiro TANAKA , Naomi KITAMOTO
IPC分类号: C07D317/72
CPC分类号: C07D317/72 , C07C317/12 , C07C317/44 , C07C317/46 , C07C2601/16 , C07C2602/08 , C07D309/28
摘要: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
-
-
-
-
-
-
-